RT Journal Article
SR Electronic
T1 Identification of optimal symptom combinations to trigger diagnostic work-up of suspected COVID-19 cases: analysis from a community-based, prospective, observational cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.23.20237313
DO 10.1101/2020.11.23.20237313
A1 Antonelli, M
A1 Capdevila, J
A1 Chaudhari, A
A1 Granerod, J
A1 Canas, LS
A1 Graham, MS
A1 Klaser, K
A1 Modat, M
A1 Molteni, E
A1 Murray, B
A1 Sudre, C
A1 Davies, R
A1 May, A
A1 Nguyen, LH
A1 Drew, DA
A1 Joshi, A
A1 Chan, AT
A1 Cramer, JP
A1 Spector, T
A1 Wolf, J
A1 Ourselin, S
A1 Steves, C
A1 Loeliger, AE
YR 2020
UL http://medrxiv.org/content/early/2020/12/01/2020.11.23.20237313.abstract
AB Background Diagnostic work-up of participants following any COVID-19 associated symptom for example, in vaccine efficacy trials will lead to extensive testing, potentially overwhelming laboratory capacity whilst primarily yielding negative results. We aimed to identify an efficient symptom combination to capture most cases using the lowest possible number of tests.Methods UK and US users of the COVID-19 Symptom Study app who reported new-onset symptoms between March-September 2020 and an RT-PCR test within seven days of symptom onset were included. Sensitivity, specificity, and number of RT-PCR tests needed to identify one RT-PCR positive case were calculated for individual symptoms and symptom combinations. A multi-objective evolutionary algorithm was applied to generate symptom combinations with good trade-offs between sensitivity and specificity.Findings The UK cohort included 122,305 individuals (1,202 RT-PCR positive). Findings were replicated in the US cohort which included 3,162 individuals (79 RT-PCR positive). Within three days of symptom onset, the COVID-19 specific symptom combination (cough, dyspnoea, fever, anosmia/ageusia) identified 69% of cases requiring 47 RT-PCR tests per case (TPC). The symptom combination with highest sensitivity at three days was fatigue, anosmia, cough, diarrhoea, headache, sore throat, identifying 96% of cases and requiring 96 TPC.Interpretation We confirm the significance of COVID-19 specific symptoms widely recommended for triggering RT-PCR. By using the data-driven optimization technique we identified additional symptoms (fatigue, sore throat, headache, diarrhoea) that enabled many more positive cases to be captured efficiently. By providing a set of solutions with optimal trade-offs between sensitivity and specificity, we produced a selection of symptom combinations that maximise the capture of cases given different laboratory capacities. This may be of use for COVID-19 vaccine developers across a range of resource settings and have more far-reaching public health implications for detection of symptomatic SARS CoV2 infection.Funding Zoe Global Limited, Department of Health, Wellcome Trust, Engineering and Physical Sciences Research Council (EPSRC), National Institute for Health Research (NIHR), Medical Research Council (MRC), Alzheimer’s Society, Massachusetts Consortium for Pathogen Readiness (MassCPR), Coalition for Epidemic Preparedness Innovations (CEPI)Evidence before this study We searched PubMed up to November 16, 2020, with the terms “COVID-19” OR “SARS-CoV-2” AND “symptom” AND “community-based”, with no date or language restrictions, to find information about symptoms associated with COVID-19 from the community setting. The search retrieved 68 articles; however, most were not relevant as related to specific subgroups (e.g. pregnant women, cancer patients) or aspects (e.g. mental health, diagnostic testing). Fever, cough, dyspnoea, tachypnoea, anosmia, and ageusia are the symptoms most commonly identified in COVID-19 patients and typically included in guidelines from the WHO and similar bodies. These data however come primarily from hospital-based studies. An assessment of the value of symptom combinations for predicting COVID-19 in the community is lacking.Added value of this study We present data from the largest, prospective community-based cohort study to date and quantify the contribution of COVID-19 symptoms and symptom combinations to COVID-19 case-finding. Our study is unique in that it simulates PCR testing in a clinical trial. Using RT-PCR as the gold standard for detecting COVID-19, we assessed the sensitivity and specificity of symptoms occurring within three days of symptom onset. An analysis of symptoms occurring within seven days of symptom onset aimed to capture delayed symptom triggers. We confirm the significance of fever, cough, and anosmia/ageusia, widely used to trigger RT-PCR testing and identified fatigue, headache, sore throat, and diarrhoea as additional symptoms for efficient COVID-19 case finding.Implications of all the available evidence The applied methodology enables the selection of symptom combinations to maximise the capture of cases while taking account of specific laboratory capacity. Our findings not only have important implications for COVID-19 vaccine developers to optimise the choice of triggering symptoms for diagnostic work-up COVID-19 vaccine efficacy trials, but also have wider public health implications for early detection of symptomatic SARS-CoV-2 infection.Competing Interest StatementJW, RD, JCP, AM are employees of Zoe Global Ltd. ATC reports grants from Massachusetts Consortium on Pathogen Readiness, during the conduct of the study; personal fees from Pfizer Inc., grants and personal fees from Bayer Pharma; CEPI (authors AC, JG, JPC, AEL) funds clinical trials of COVID-19 vaccines. All other authors declare no competing interests.Funding StatementZoe Global Limited, Department of Health, Wellcome Trust, Engineering and Physical Sciences Research Council (EPSRC), National Institute for Health Research (NIHR), Medical Research Council (MRC), Alzheimer's Society, Massachusetts Consortium for Pathogen Readiness (MassCPR), Coalition for Epidemic Preparedness Innovations (CEPI)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics has been approved by KCL Ethics Committee REMAS ID 18210, review reference LRS-19/20-18210 and all participants provided consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collected in the COVID-19 Symptom Study smartphone application are being shared with other health researchers through the UK National Health Service-funded Health Data Research UK (HDRUK) and Secure Anonymised Information Linkage consortium housed in the UK Secure Research Platform (Swansea, UK). Anonymised data are available to be shared with HDRUK researchers according to their protocols in the public interest (https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259). US investigators are encouraged to coordinate data requests through the Coronavirus Pandemic Epidemiology Consortium (https://www.monganinstitute.org/cope-consortium). https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259